玻璃体腔注射雷珠单抗联合复合小梁切除术治疗新生血管性青光眼.docVIP

精品论文 参考文献 玻璃体腔注射雷珠单抗联合复合小梁切除术治疗新生血管性青光眼 （1.湖北医药学院附属十堰市太和医院 湖北 十堰 442000；2.上海交通大学附属第六人民医院眼科 上海 200233） 【摘 要】目的：探讨玻璃体腔注射雷珠单抗联合复合小梁切除术治疗新生血管性青光眼疗效。方法：18例 (19眼)新生血管性青光眼患者给予玻璃体内注射10mg/mL雷珠单抗0. 05 mL,后续联合复合小梁切除术及全视网膜光凝术。术后随访 6-12个月, 观察术后视力、眼压、 虹膜新生血管及并发症情况。结果：所有术眼虹膜新生血管均在注射雷珠单抗后3 d内消退; 1例 1眼患者在全视网膜光凝后1月虹膜新生血管复发,再次注入雷珠单抗,加行周边视网膜冷凝,虹膜新生血管消退。复合小梁切除术后1周平均眼压为 ( 17. 5plusmn;3.2) mmHg , 6个月为 ( 19. 1 plusmn; 2. 1) mmHg , 与雷珠单抗注入前眼压( 50 . 7plusmn;6 . 3) mmHg相比差异均有统计学意义 (均为 P lt; 0.05)。治疗前后视力差异无统计学意义。随访期间未发现眼内出血、视网膜脱离、眼内炎、并发性白内障等并发症发生。结论：玻璃体腔注射雷珠单抗联合复合小梁切除及全视网膜光凝术可明显消退虹膜新生血管、控制眼压, 是治疗新生血管性青光眼的一种安全有效的方法。 【关键词】新生血管性青光眼；雷珠单抗；复合小梁切除术 【中图分类号】R775 【文献标识码】A 【文章编号】1004-6194（2015）02-0105-02 Treatment of Intravitreal Ranibizumab Joint Compound Trabeculectomy for Neovascular Glaucoma Zhou Xia1 Tan Yeshuang1* Hua Yanjun2 【Abstract】Objective：To study the validity of intravitreal ranibizumab joint compound trabeculectomy for neovascular glaucoma(NVG). Methods：19 eyes of 18 cases with NVG received intravitreal injection of 0.05mL ranibizumab (10mg/mL), followed by compound trabeculectomy and panretinal laser photocoagulation. All patients were followed up for 6-12 months, observing visual acuity, intraocular pressure(IOP), iris neovascularization and other complications. Results：All eyes performed iris neovascularization faded 3 days after the injection of ranibizumab. One eye performed iris neovascularization recurrence 1 month after panretinal photocoagulation. And with the reinjection ranibizumab and peripheral retinal cryotherapy, the iris neovascularization subsided. The IOP were (17. 5 plusmn; 3.2) mmHg One week after compound trabeculectomy, and (19. 1 plusmn; 2. 1) mmHg 6 months after compound trabeculectomy. Both were significantly lower than the IOP (50.7 plusmn; 6.3 mmHg) before intravitreal ranibizumab (Both P lt;0.05). Visual acuity before and after treatment showed no significant difference. During the follow-up no intraocular hemorrhage, retinal detachmen